Lead Discovery Center Gmbh

Merck Sharp + Dohme Corp.

Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Msd Italia S.r.l.

Merck + Co., Inc.

Bayer Intellectual Property Gmbh

Instituto Di Ricerche Di Biologia Molecolare P. Angeletti

Qurient Co., Ltd.

Sotio A.s.

Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.p.a.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

Istituto Di Ricerche Di Biologia Molecolare P. Angletti Spa

Qli5 Therapeutics Ag

Uwe Koch

Frank Narjes

Joerg Habermann

Ian Stansfield

Jan Eickhoff

Peter Nussbaumer

Nigel J Liverton

Anandan Palani

Hao Wu

Peng Li

Casey Cameron McComas

Xing Dai

Shuwen He

Hong Liu

Vincenzo Summa

Richard Soll

Xuanjia Peng

Steven Harper

Jesus Maria Ontoria Ontoria

Cristina Gardelli

Gunther Zischinsky

Bert Klebl

Axel Choidas

Qun Dang

Nicolas Zorn

Zhong Lai

Carsten Schultz-Fademrecht

Simona Ponzi

Gerd Rühter

Tim Bergbrede

Maria Falkenberg-Gustafsson

Nils-Göran Larsson

Claes M Gustafsson

Raffaella Di Lucrezia

Anke Unger

Axel Ullrich

Philip Jones

Ravi P Nargund

Dong Xiao

Michael Rowley

Marco Ferrara

Alessia Petrocchi

Rita Scarpelli

Clare London

Marco Poma

Ester Muraglia

Jaeseung Kim

Giovanna Pescatore

Olaf Kinzel

Benedetta Crescenzi

Kiyean Nam

Licia Tomei

Victor Giulio Matassa

Dongsik Park

Stefania Colarusso

Yeejin Jeon

Mooyoung Seo

Monica Donghi

Philippe Jean Sigfried Neuner

Donghoon Yu

Caterina Torrisi

Carsten Schulz-Fademrecht

Claudio Giuliano

Vicenzo Summa

Benjamin Gerlach

Jeongjea Seo

Altamura Sergio

Alexander Wolf

Carsten Degenhart

Julian Engel

Seung-Joo Lee

Wongyun Ahn

Robert Huber

The present invention relates to pyrazolo [1,5-a][1,3,5]triazine and pyrazolo [1,5-a]pyrimidine derivatives having Formula I: and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors

The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.

Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer

The invention provides novel 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.

4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. 

Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.

Pharmaceutically active pyrazolo-triazine derivatives

Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases

Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases

The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase. 

Pharmaceutically active disubstituted triazine derivatives

Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.

The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.

Pharmaceutically active compounds as Axl inhibitors

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment. 

Quinolin-4-one and 4-oxodihydrocinnoline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)

The present invention relates to macrocyclic compounds of formula (I): wherein W, n, m, R, R, R, R, R, R, M, Z and ring B are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus. 

Macrocyclic compounds as antiviral agents

Compounds of the formula (I) wherein A, B, D, M, Ar, W, X, Y, Z and Rare as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed. 

Antiviral indoles

Compounds of the formula (I): wherein A, B, D, M, Ar, W, X, Y, Z and Rare as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed.

Growing community of inventors

Dortmund, Germany

Uwe Koch